Ads
related to: hcv polymerase inhibitors for diabetes mellitus list of names- FAQs About Hepatitis C
Get The Facts About Hepatitis C &
Read About A Treatment Option Today
- A Hep C Treatment Regimen
Ready To Treat Your Hep C?
Learn About A Treatment Option Here
- Risks Of Hepatitis C
Read About The Risks Of Hep C And
Explore A Hep C Treatment Here.
- Find A Hep C Provider
Ready To Take The Next Step? Find
A Hep C Provider Near You Today!
- FAQs About Hepatitis C
Search results
Results From The WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Dasabuvir is in the HCV NS5B polymerase inhibitor class of medication. [3] Dasabuvir was approved for medical use in 2014. [5] It is on the World Health Organization's List of Essential Medicines. [6] In the United States, it is approved by the Food and Drug Administration (FDA) only for use in combination with ombitasvir/paritaprevir/ritonavir ...
Asunaprevir (NS3/4A protease inhibitor) Beclabuvir (NS5B RNA polymerase inhibitor) Dasabuvir (NS5B RNA polymerase inhibitor) Grazoprevir (NS3/4A protease inhibitor) Paritaprevir (NS3/4A protease inhibitor) Simeprevir (NS3/4A protease inhibitor)
Ribonucleotide reductase and DNA polymerase inhibitor. [11] Acute lymphoblastic leukaemia and acute myeloid leukaemia: Myelosuppression, hypokalaemia, cytokine release syndrome, Stevens–Johnson syndrome (uncommon), toxic epidermal necrolysis (uncommon) and pancreatitis (uncommon) Cytarabine: SC, IM, IV, IT: DNA polymerase inhibitor, S-phase ...
[2] [6] Simeprevir is a HCV protease inhibitor. [2] Simeprevir was developed by Medivir AB and Janssen Pharmaceutica. [7] It was approved for medical use in the United States in 2013. [8] It was removed from the World Health Organization's List of Essential Medicines in 2019. [9] [10] It is not available as a generic medication as of 2015. [6]
In March 2020, sofosbuvir/velpatasvir was approved for use in the United States to treat hepatitis C virus (HCV) in children ages six years and older or weighing at least 37 pounds (17 kilograms) with any of the six HCV genotypes—or strains—without cirrhosis (liver disease) or with mild cirrhosis.